Gorilla Gains Ahead of Q1 Earnings
Gorilla Technology Group Inc. (NASDAQ: GRRR) shares improved in price Thursday. The London-based company, a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, today announced a series of significant developments underscoring its confidence in long-term value creation and sustained operational momentum.Gorilla successfully completed the repurchase of over $1.8 million worth of its own shares in April and May, capitalising on market dislocation and reinforcing its belief in the intrinsic value of the business. This strategic deployment of capital reflects the company's confidence in its growth trajectory, operational execution and long-term fundamentals.This brings the company's cumulative share repurchases under the current buy-back programme to $5.4 million in the past twelve months, leaving $4.6 million remaining under the $10 million authorized by the Board. The company remains open to further opportunistic repurchases as cash buffers continue to strengthen.Gorilla will release its financial results for the first quarter of 2025 in the first half of June, which will be followed by an investor call. The company is poised to report continued progress across key markets including Southeast Asia, U.S.A., Latin America and the U.K., driven by its AI-powered smart infrastructure solutions. Call information will be circulated shortly.GRRR shares captured 29 cents, or 1.9%, to $15.76.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


